佐力药业(300181.SZ)拟3.56亿元收购西藏未来旗下多种微量元素注射液资产组

Core Viewpoint - Zhaoli Pharmaceutical (300181.SZ) announced the signing of an asset acquisition agreement with Tibet Future Biopharmaceutical Co., Ltd. and its subsidiaries for a total price of RMB 356 million to acquire a multi-trace element injection asset group [1] Group 1: Acquisition Details - The asset group includes already marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development product "Multi-trace Element Injection (III)" [1] - The acquisition encompasses research and production technical data, marketing licenses, trademarks, patents, contractual rights and obligations, and employee labor relations [1]